Metrics raised 1
- Wafer-ingot capacity target increased from 6 GW to 9 GW, with commissioning expected FY29
Metrics cut 1
- FY27 EBITDA guidance of ₹1,500-1,600 crores deferred; to be revisited at H1 results (prior guidance was ₹1,500-1,600 crores)
Event Participants
Executives
4 Sameer Nagpal, Ranjan Jindal, Arun Mittal, Rinal Shah
Analysts
11 Akshay Mane, Bhagwat Nayak, Deepak Purswani, Karan Gupta, Mohammed Taha Ansari, Praveen Sahay, Rishabh Modi, Ritesh Abbi, Sahil Sheikh, Siddharth, Vishal Shah
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹1,560 crores | +38% YoY, +8% QoQ; driven by DCR mix and higher dispatch volumes |
| Module Dispatches | 1,006 MW | +32% YoY, flat QoQ; highest-ever quarterly volume |
| Realization | ₹15.02/Wp | +8% QoQ; DCR product (₹21-22+/Wp) lifted blended ASP; not price-driven |
| COGS per Watt | +₹1.86/Wp | Metal/crude-linked input inflation (frames, busbar, EVA) and lagged Chinese cell cost pass-through |
| EBITDA | ₹126 crores | Margin 8.06%; entire movement in a single COGS line; realization improved, all other cost lines improved |
| EBITDA per Watt | ₹1.25/Wp | Down vs prior quarters; pass-through clauses cover only cell, not BOM |
| PAT | ₹19.78 crores | Reflects margin compression despite revenue growth |
| Order Book | 7.9 GW | 7.1 GW large accounts (non-DCR); DCR/distribution booked outside order book |
| Capex Deployed (Q1) | ~₹500 crores | 80% toward module facility, balance toward cell plant |
| Long-term Debt | Nil | Working capital utilization down; net debt/equity negligible |
| DCR Volume Sold | 76 MW | Exceeds entire FY26 DCR volume; expected to grow 2-2.5x per quarter |
Geographic & Segment Commentary
Domestic - DCR: Sold 76 MW in Q1, exceeding FY26 full-year volumes; multiple domestic sales procurement agreements locked in. DCR modules primarily serve distribution network with some mid-market allocation; DCR realization of ₹21-22+/Wp vs blended ₹15.02/Wp. Company not yet taking orders backed by own cell production; that starts once the cell line is closer to commissioning.
Domestic - Distribution: Monthly run rate doubled from ~40 MW last year to ~80 MW; network now stands at 119+ distributors and 757+ dealers across 24 states and 500 districts. Channel increasingly strategic for PM Surya Ghar and PM-KUSUM policy-driven demand; richest gross margin segment.
Domestic - Mid-Market: Sales team doubled in the year; targeting midsized EPCs and C&I clients where demand pool is broadening. Expects ~₹0.50/Wp higher price realization versus large accounts.
Domestic - Large Accounts (Utilities/IPPs/C&I): 7.1 GW order book entirely non-DCR; base-load volumes with tighter margins. ALMM-2 deferment to December 2026 has unlocked ~50 GW/year C&I demand conversations previously in limbo.
BESS (VSL Powerhive): 7.5 GWh assembly plant in Chennai - equipment delivery November 2026, installation January 2027, target CO March 2027. Phase-1 7.5 GWh LFP cell plant (Gen 2 large format) targeting Q4 FY29 CO; land/incentive finalization by September 2026. First 20 MWh utility-scale order executed; Powerhive brand launched.
Company-Specific & Strategic Commentary
Backward Integration at Gangaikondan: 6 GW module facility fully funded and commissioning on June 29 as promised; 9 GW cell plant on schedule with first cell targeted Q4 FY27 (~70% backward integration); Board approved wafer-ingot scale-up from 6 GW to 9 GW. All three stages co-located in a single fence - sharing utility base, shell infra, eliminating transport - with modular capacity design enabling capital alignment to policy/demand.
Technology & Automation: Completed transition from M10R to G12R module platform (higher watt peak, lower conversion cost). New lines at Vallam and Gangaikondan reduced manpower deployment by ~40% with comparable improvement in line cycle time; substantial conversion cost optimization at full utilization.
Cost Discipline Program: Value engineering across BOM, alternate vendor procurement strategy, logistics rationalization, moderated discretionary overheads, tightened inventory cycle. Other expenses per watt down 6%, finance cost per watt down 11% - early reads, full benefit expected over coming quarters.
International Expansion: Dedicated international team formed; global buyers diversifying sourcing toward verifiable India-built provenance. EcoVadis Platinum rating received second consecutive time (top 1% of 200,000 companies assessed), strengthening standing with global buyers, lenders, EU and U.S. premium positioning.
Capital Plan: ~₹4,700-5,000 crores capex in FY27, similar in FY28; funded 70:30 debt:equity, financial closure in process. Committed capital does not breach leverage guardrails at peak drawdown; no long-term debt drawn to date.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 EBITDA | ₹1,500-1,600 crores (earlier guidance) | To be revisited at H1 results; management says Q1 absorbed one-off cost hits, wants clarity on ALMM-2 policy direction, DCR pricing, distribution penetration before reconfirming |
| EBITDA Margin | 8% area for near term | Management noted margins "could get better" if cost inflation normalizes; cell commissioning only in Q4 limits near-term upside |
| Cell Capacity | 9 GW commissioning Q4 FY27 | Ramp standard 6-month industry practice; full 9 GW available from FY28 |
| Cell Utilization (FY28) | 40-50% first year | 6 months ramp-up embedded; utilization builds as DCR order book scales |
| DCR Volume Growth | 2x-2.5x per quarter | Based on secured domestic cell supply agreements and distribution channel ramp |
| Capex | ~₹5,000 crores FY27, similar FY28 | 70:30 debt:equity split; debt drawdown begins end of August 2026 |
| Wafer-Ingot | 9 GW commissioning FY29 | Board approved scale-up from 6 GW; project cost ~₹5,600 crores |
Risks & Constraints
| Risk | Context |
|---|---|
| ALMM 2 Policy Uncertainty | Mandate toggled between enforcement and deferment (now December 2026); further extension discussions ongoing. Directly impacts customer procurement timing - grandfathered non-DCR projects (~80 GW) and C&I demand held in limbo; management refraining from volume/margin guidance until policy clarity emerges |
| Input Cost Inflation | Gulf conflict drove aluminum/copper (35% of BOM basket) and crude-linked EVA (20% of BOM basket) higher; cost escalation clauses cover only cell, not BOM - effectively passing through only a minority of raw material cost risk; Chinese cell spot prices ($0.04/Wp + 27.5% BCD) add further procurement cost pressure |
| Industry Oversupply | ~200 GW module capacity industry-wide vs demand; competitive intensity prevented full pass-through of costs; management notes capacity rationalization expected but timing uncertain |
| Margin Compression | Q1 EBITDA margin at 8.06% vs ~16% historical level; recovery contingent on DCR mix scaling, cell commissioning, cost program maturity - multiple moving parts |
Q&A Highlights
Margin, Spread & Cost Pass-Through
Question: What was the spread per watt this quarter, and why didn't cost escalation clauses protect margins? (Deepak Purswani, Svan Investments)
Answer: EBITDA of ₹125 crores over 1 GW volume = ₹1.25/Wp. Escalation clauses cover only cell costs, not BOM. Metal/EVA inflation and oversupply prevented full cell pass-through. Cost pressure is identified, concentrated in COGS line, largely transitory. (Ranjan Jindal)
Question: Will margins recover to the prior 16% range in Q2? Peer margins only dropped 1-2% while ours nearly halved. (Akshay, UBS)
Answer: Q2 will still carry some impact of unabsorbed prices. DCR/channel mix will help. Peer comparison not meaningful - other players have captive cells; we don't until Q4 FY27. Cell commissioning is the inflection point. (Sameer Nagpal, Ranjan Jindal)
DCR Strategy & Realization
Question: Is the DCR margin delta vs non-DCR significant? Cell makers retain most margin. (Praveen Sahay, PL Capital)
Answer: DCR delivers more than non-DCR, but serious volumes only begin flowing now - 76 MW in Q1 out of ~1 GW. Expect stabilization as DCR scales; DCR realizations ₹21-22+/Wp. (Ranjan Jindal)
Question: What's the price/margin differential between distribution and large accounts? (Bala Murali Krishna, Oman Investments)
Answer: Price realization ranges ₹1-1.5/Wp better in distribution over key accounts. Distribution is the richest margin segment. DCR cells primarily service distribution, some mid-market; large accounts only after own cell line commissions. (Sameer Nagpal)
Order Book & Volume Outlook
- Question: How much of the ~8 GW order book is executable this year? (Deepak Purswani, Svan Investments)
- Answer: Capacity of 15.5 GW can deliver 9-9.5 GW for the full year, but won't take negative-margin orders. Customer plans changed post-ALMM deferment; need one more quarter for clarity on volumes and pricing. (Ranjan Jindal)
Demand Environment
- Question: What's the eligible non-DCR book size and demand across utilities/C&I/retail? (Karan Gupta, Asit C Mehta Investments)
- Answer: Grandfathered non-DCR ~80 GW; C&I ~15 GW/year (6-7 GW rooftop). Utility market 30-35 GW AC this year; PM Surya Ghar + KUSUM combined 14-15 GW. Fresh tendering 35-40 GW executes in FY28. Data centers (25-26 GW in 5 years) with 70-80% solarization create 5x solar demand multiplier. (Rinal Shah)
Cell Plant Ramp & Utilization
- Question: What utilization can we expect for the cell plant in FY28? (Mohammed Taha Ansari, Taha Capital Management)
- Answer: Assuming 6-month ramp per industry practice, targeting 40-50% utilization for the full first year. (Rinal Shah)
Capex & Balance Sheet
- Question: What's the capex phasing and debt funding plan? (Sahil Sheikh, Anand Rathi)
- Answer: ~₹5,000 crores in FY27, similar in FY28. Plans at 75:25 debt:equity moving to 70:30 overall. Financial closure in process; debt drawdown begins late August. Wafer-ingot 9 GW project cost ~₹5,600 crores. (Ranjan Jindal)
Competitive Positioning
- Question: What distinguishes Vikram Solar from peers who may struggle through this downturn? (Ritesh Abbi, Kingsman Wealth)
- Answer: Four pillars: (1) best-in-class products with 20-year technology leadership, (2) integrated world-class manufacturing (module → cell → wafer-ingot), (3) cost-efficient structure, (4) diversified customer base across large accounts, mid-market, distribution. Combination drives stability and better realization. (Sameer Nagpal)
FY27 Guidance
- Question: Is the earlier ₹1,500-1,600 crores EBITDA guidance still valid? Will margins stay at ~8%? (Bhagwat, Prosperity Wealth)
- Answer: Revisit at H1 results. Q1 absorbed policy, war, and inventory effects. Environment continuing, competitive intensity unchanged - margins should "broadly trend in this space, but could get better." No guidance update until ALMM-2 and pricing clarity. (Ranjan Jindal, Sameer Nagpal)
Key Takeaway
Vikram Solar delivered its highest-ever quarterly volume of 1,006 MW (+32% YoY) and revenue of ₹1,560 crores (+38% YoY), but EBITDA margin compressed to 8.06% (₹1.25/Wp) as war-driven metal/crude cost inflation and lagged Chinese cell prices hit a single COGS line without full pass-through - a margin hit amplified by the absence of captive cells. Management frames Q1 as a repositioning quarter: 76 MW DCR volumes (exceeding FY26 totals), distribution run-rate doubled to ~80 MW/month across 119+ distributors, mid-market sales team doubled for ₹0.50/Wp realization uplift, and the 6 GW Gangaikondan module line commissioned on schedule. The 9 GW cell plant remains on track for Q4 FY27, wafer-ingot (9 GW, ~₹5,600 crores) breaking ground shortly, and BESS assembly targeting CO March 2027 - funded via 70:30 debt:equity with no long-term debt drawn. The company has deferred its FY27 EBITDA guidance of ₹1,500-1,600 crores to H1 results, citing ALMM-2 policy fluidity (C&I deferment to December 2026) and a 50 GW/year C&I demand pool awaiting clarity. Watch points include DCR mix scaling (targeting 2-2.5x quarterly growth), cost normalization as metal/crude prices settle, and the strategic shift toward a three-tier customer base that management expects to structurally lift realizations as the integrated platform captures cell margins by FY28.